# US 2019/0161502 A1 · 1,4-oxazines useful as selective bace1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0161502 A1
- Document ID: US20190161502A1
- Status: Published application
- Kind: A1
- Application number: 16/323,827
- Filed: 2017-08-18
- Published: 2019-05-30
- Earliest claimed: 2016-08-26
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Steven James Green; Erik James Hembre, II; Dustin James Mergott
- Web page: https://patentgrep.com/patent/US20190161502A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, useful as a BACE1 inhibitor.

## Claims

### Claim 1

A compound of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound or salt according to claim 1 wherein the methyl at position 3 is in the cis configuration relative to the trifluoromethyl at position 6 on the oxazine ring:

### Claim 3

A compound which is N-[3-[(3R,6R)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluoro-phenyl]-5-cyano-thiazolo[5,4-b]pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A method of treating Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

A method of preventing the progression of mild cognitive impairment to Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients.

### Claim 10 (depends on 1)

A process for preparing a pharmaceutical composition, comprising admixing a compound or a pharmaceutically acceptable salt thereof according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients.

### Claim 11 (depends on 3)

A method of treating Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 3, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 3)

A method of preventing the progression of mild cognitive impairment to Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 3, or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 3)

A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof according to claim 3 with one or more pharmaceutically acceptable carriers, diluents, or excipients.
